Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +0.36% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.28 | N/A | +0.36% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the current progress of their projects. They emphasized their commitment to pipeline advancement despite not providing specific guidance.
We are pleased with our progress in the quarter.
Our focus remains on advancing our pipeline.
IDEAYA Biosciences I's earnings report shows a positive surprise on EPS, indicating better-than-expected performance in that area. The stock reacted positively, rising by 1.25%. However, the lack of revenue data and guidance may leave investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UBIQUITI INC
May 7, 2021